Faculty of Psychology, University of Barcelona, 08007 Barcelona, Spain.
Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, 33011 Oviedo, Spain.
Curr Oncol. 2023 Oct 19;30(10):9205-9216. doi: 10.3390/curroncol30100665.
The purpose of the study was to identify subgroups of advanced cancer patients who experienced grade 3-4 toxicities as reported by their oncologists as well as identify the demographic, clinical, and treatment symptom characteristics as well as QoL outcomes associated with distinct profiles of each patient. A prospective, multicenter, observational study was conducted with advanced cancer patients of 15 different hospitals across Spain. After three months of systemic cancer treatment, participants completed questionnaires that evaluated psychological distress (BSI-18), quality of life (EORTC QLQ-C30) and fatigue (FAS). The most common tumor sites for the 557 cancer patients with a mean age of 65 years were bronchopulmonary, digestive, and pancreas. Overall, 19% of patients experienced high-grade toxicities (grade 3-4) during treatment. Patients with recurrent advanced cancer, with non-adenocarcinoma cancer, undergoing chemotherapy, and a showing deteriorated baseline status (ECOG > 1) were more likely to experience higher toxicity. Patients who experienced grade 3-4 toxicities during cancer treatment had their treatment suspended in 59% of the cases. Additionally, 87% of the patients had a dose adjustment or a cycle delayed in their treatment due to a high risk of dying during treatment. Future research should focus on identifying interventions to reduce high-grade toxicities and improve quality of life in cancer patients.
本研究旨在确定报告为肿瘤学家的 3-4 级毒性的晚期癌症患者亚组，并确定与每位患者的不同特征相关的人口统计学、临床和治疗症状特征以及生活质量结局。对来自西班牙 15 家不同医院的 557 名晚期癌症患者进行了前瞻性、多中心、观察性研究。在接受三个月的系统癌症治疗后，参与者完成了评估心理困扰（BSI-18）、生活质量（EORTC QLQ-C30）和疲劳（FAS）的问卷。对于 557 名平均年龄为 65 岁的癌症患者来说，最常见的肿瘤部位是支气管肺、消化系统和胰腺。总体而言，19%的患者在治疗过程中经历了 3-4 级高等级毒性。患有复发性晚期癌症、非腺癌癌症、接受化疗以及基线状况恶化（ECOG>1）的患者更有可能经历更高的毒性。在癌症治疗期间经历 3-4 级毒性的患者中有 59%的患者暂停了治疗。此外，由于治疗期间死亡风险高，87%的患者因治疗剂量调整或周期延迟。未来的研究应集中于确定干预措施，以减少癌症患者的高等级毒性并提高生活质量。
